From the Editor

The fight for dominance over healthcare delivery, resources, and decision-making intensifies as private equity, AI, and corporate consolidation reshape the landscape. Read More ›

Drug shortages are reshaping cancer care – how can oncologists and cancer centers prepare and what do these gaps mean for treatment decisions, access, and affordability? Read More ›

A coalition of more than 40 health insurers recently announced plans for prior authorization reform. Read More ›

We have come so far from the local physician who made house calls and was paid in cash or goods. Now, it seems that no matter what a doctor prescribes, there is no shortage of external opinions as to whether that choice was appropriate. Read More ›

Patients waited an average of 2+ months and up to 16.8 months to receive their medication. Read More ›

The common issue addressed by lawsuits is the removal of human beings to review and make determinations regarding the appropriateness of care. While mainly focused now on algorithms, these factors seem to be an indicator of future health plan litigation involving artificial intelligence. Read More ›

2024 has been a tumultuous year. Every one of our editorials explored a different way that cancer practices faced new challenges to their patients’ access to the care they need and the resources that can ease the emotional and financial burdens of their treatment. Read More ›

Patient care is very personal. The physicians and care teams of cancer practices constantly assess what they see and hear relating to the patients when they are in the office. Unfortunately, patients are outside the office more than they are in front of the care team. Read More ›

As patients search for financial options, medical practices, health systems, and patient advocacy organizations may want to increase diligence on options and referral opportunities that come to them offering to “help” patients.  Read More ›

Medical practices that prescribe drugs for their patients have an ethical and legal liability to obtain drugs that meet safety, efficacy, and quality standards. Employers have a fiduciary responsibility to their employees to provide health benefit plans that follow important US drug safety measures and help to ensure that counterfeit and/or unsafe drugs are not provided to unsuspecting employees. Yet, some specialty pharmacies and vendors are offering international drugs to employee health benefit plans. Read More ›